Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other hematologic neoplasm 2Myeloid 2Gastrointestinal 2Sarcoma 1Genitourinary 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1

Interventions

Temozolomide 166Magnetic Resonance Spectroscopy 131Radiotherapy 97Specimen Handling 81Radiosurgery 61Cyclophosphamide 56pembrolizumab 52Bevacizumab 52Radiation 48Nivolumab 48Carboplatin 36Biopsy 33Irinotecan 29Lomustine 25Etoposide 25Vincristine 24Topotecan 23Ipilimumab 23Blood Specimen Collection 23Cisplatin 22dinutuximab 21fludarabine 19Surgical Procedures, Operative 19Radiotherapy, Intensity-Modulated 19X-Rays 18abemaciclib 16Mental Status and Dementia Tests 16Granulocyte-Macrophage Colony-Stimulating Factor 16Pemetrexed 15atezolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
guadecitabine × CNS × 1 year × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡